|
Wed, 09/18/2019 - 17:51 |
Heroes to Hives Helping Veterans Heal |
Michigan State ... |
|
Thu, 12/13/2018 - 11:41 |
Novartis receives European Commission approval for self-administration of Xolair across all indications |
Novartis |
|
Sun, 12/02/2018 - 23:09 |
New Venclexta Data Demonstrate Deep Responses in Two of the Most Common Types of Leukemia |
Genentech |
|
Wed, 11/28/2018 - 15:22 |
FDA approves first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder |
FDA |
|
Mon, 11/26/2018 - 20:32 |
Pfizer Receives Six Months Pediatric Exclusivity for LYRICA (pregabalin) |
Pfizer |
|
Sun, 11/25/2018 - 20:25 |
FDA Approves The ACTpen For Genentechs ACTEMRA, A Single-Dose, Prefilled Autoinjector For The Treatment Of Rheumatoid Arthritis, Giant Cell Arteritis And Two Forms Of Juvenile Arthritis |
Genentech |
|
Tue, 11/06/2018 - 11:32 |
FDA grants priority review for Dupixent (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis |
Genzyme |
|
Fri, 11/02/2018 - 12:35 |
Chickenpox, also known as varicella, is a disease dreaded by both parents and children alike. |
Lifespan |
|
Thu, 10/18/2018 - 22:57 |
FDA approves asthma indication for Dupixent (dupilumab) |
Genzyme |
|
Tue, 10/16/2018 - 06:24 |
Dupixent (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps |
Genzyme |
|
Wed, 10/10/2018 - 18:35 |
Sanofi Presents 8-Year Data on Lemtrada (Alemtuzumab) |
Genzyme |
|
Tue, 10/09/2018 - 17:14 |
OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression over Five Years in Relapsing and Primary Progressive Multiple Sclerosis |
Genentech |
|
Sun, 10/07/2018 - 21:17 |
More Than 30 Data Presentations from Sanofi Genzymes Multiple Sclerosis Franchise to Be Featured at the 34th ECTRIMS Congress |
Genzyme |
|
Mon, 10/01/2018 - 14:43 |
Genentech to Present Five-Year OCREVUS (Ocrelizumab) Efficacy and Safety Data in Relapsing and Primary Progressive Multiple Sclerosis at ECTRIMS |
Genentech |
|
Fri, 09/28/2018 - 04:57 |
FDA Approves Genentech's Xolair (Omalizumab) Prefilled Syringe Formulation |
Genentech |
|
Sat, 09/15/2018 - 11:51 |
Positive Phase 3 results presented for Dupixent (dupilumab) show significant improvement on multiple measures of disease severity in adolescents with moderate-to-severe atopic dermatitis |
Genzyme |
|
Thu, 09/13/2018 - 18:58 |
FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis |
Genentech |
|
Sun, 08/12/2018 - 10:07 |
FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies |
Genentech |
|
Fri, 08/03/2018 - 04:03 |
Back to School: Immunizations, Food Allergies & Independence |
Cone Health |
|
Mon, 07/16/2018 - 15:17 |
Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA (canagliflozin) is Being Stopped Early for Positive Efficacy Findings |
Johnson and Johnson |
|
Fri, 07/13/2018 - 16:57 |
U.S. FDA Extends Review Timeline for INVOKANA (canagliflozin) Supplemental New Drug Application |
Johnson and Johnson |
|
Wed, 07/11/2018 - 03:25 |
Parents Health Knowledge Could Affect How Many Reactions Their Kids with Food Allergies Have and How Well They Are Managed |
AAAAI |
|
Wed, 07/11/2018 - 03:01 |
Genentech Announces Submission of Supplemental New Drug Application for Venclexta for People With Previously Untreated Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy |
Genentech |
|
Thu, 07/05/2018 - 23:13 |
Cold Urticaria Is Real: We May Need to Ban Winter |
American Counci... |
|
Sun, 07/01/2018 - 22:38 |
Follow-Up Samples from the Illinois River Show No Microcystins |
Illinois Government |
